The EpiPen buyers leading price-gouging litigation against two top drugmakers secured final approval Wednesday from a federal judge in Kansas for their $345 million settlement with Pfizer Inc. affiliates that formerly manufactured the lifesaving allergy treatment sold by Mylan NV, reported Bloomberg.
Judge Daniel D. Crabtree signed off on the agreement, which resolves class action antitrust claims brought against Pfizer in the US District Court for the District of Kansas on behalf of “end payers” like insurers, pension funds, and consumers.
Rex Sharp, a Prairie Village lawyer representing the plaintiffs, said in an email that his clients were pleased that Pfizer had agreed to the settlement while noting it still requires court approval.
Related: Pfizer Pays To Exit EpiPen Price-Gouging Case
He said the plaintiffs looked forward to trying the remaining claims against Mylan before a jury.
The litigation dates to 2016, when numerous class action lawsuits were filed against Pfizer, Mylan and other defendants alleging they engaged in anticompetitive conduct in connection with their marketing of the EpiPen.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
